Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIAN phase III adjuvant sacituzumab govitecan + zimberelimab in resected NSCLC without pathological complete response after neoadjuvant chemoimmunotherapy
2024-512960-75-00Phase 3Authorised
- Sponsor
- Fundación GECP
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacituzumab govitecan and zimberelimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Disease-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
sacituzumab govitecanzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512960-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512960-75-00.